Argon Versus Selective Laser Trabeculoplasty in Younger Patients

Yingwei, Liu; Birt, Catherine M.

doi:10.1097/ijg.0b013e318202791c

Cited by 30 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another recent meta-analysis of SLT vs ALT demonstrated the number of patients achieving ≥3 mmHg or ≥20.0% decrease from baseline was 40%–85% of patients with a summative result of 60.1% 18. However, the baseline mean pretreatment IOP in these studies ranged from 19.2 to 24.0 mmHg, while our baseline IOP measurements were lower at 18.26 mmHg in the MLT group and 16.85 mmHg in the SLT group 19–22…”

Section: Discussioncontrasting

confidence: 67%

Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma

Abramowitz

Chadha

Kouchouk³

et al. 2018

OPTH

View full text Add to dashboard Cite

AimThe aim of this study was to prospectively compare the efficacy, safety, and tolerability of selective laser trabeculoplasty (SLT) vs micropulse laser trabeculoplasty (MLT) in reducing intraocular pressure (IOP) in open-angle glaucoma patients.Patients and methodsIn all, 38 patients were randomized to 360° MLT and 31 patients were randomized to 360° SLT. IOP was measured at intervals of 1 hour and 1, 1–6, 6–12, 6–24, 24–36, and 36–52 weeks. Patients completed a survey 1 week after the procedure. Patients with end-stage, neovascular, uveitic, or angle-closure glaucoma were excluded. Treatment response was defined as an IOP reduction of ≥20.0% or ≥3 mmHg from baseline.ResultsIOP was lowered to ≥3 mmHg from baseline among 37.0% of the micropulse patients and 36.0% of patients in the selective laser group at 24–52 weeks. Similarly, 29.6% of the micropulse patients and 36.0% of the selective laser patients experienced a 20.0% IOP decrease from baseline during the 24–52-week interval (P=0.77). Both groups revealed similar reductions in IOP as absolute values and percentage decreases from baseline at all intervals up to 52 weeks post treatment. There were more treatment failures in the micropulse group up to 52 weeks post laser treatment; however, this was not statistically significant. The micropulse group reported less pain both during and after the procedure (P=0.005).ConclusionMicropulse trabeculoplasty has demonstrated similar efficacy to SLT over a 52-week follow-up period with less discomfort experienced both during and after the procedure.

show abstract

Section: Discussioncontrasting

confidence: 67%

Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma

Abramowitz

Chadha

Kouchouk³

et al. 2018

OPTH

View full text Add to dashboard Cite

show abstract

“…12 Likewise, the success rate of our subjects was in agreement to previous randomized controlled trials, showing that selection bias was unlikely to be significant. 19,21,29 Our study had its limitations. Firstly, the duration of observation was only 1 month post-SLT.…”

Section: Discussionmentioning

confidence: 91%

“…[19][20][21][22][23] Identification of responders would therefore be important in the clinical application of SLT. By far the most well-proven predictor for SLT success is a higher baseline IOP.…”

Section: Discussionmentioning

confidence: 99%

Correlation of Intraocular Pressure Between Both Eyes After Bilateral Selective Laser Trabeculoplasty in Open-angle Glaucoma

Lee

Wong

et al. 2016

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…Liu and Birt 27 in Canada compared the effectiveness of 1801 ALT and 1801 SLT in lowering IOP in a younger cohort of patients (o60 years). Forty-two patients (42 eyes) were included in the study, with 22 randomised to ALT and 20 randomised to SLT.…”

Section: Slt Vs Altmentioning

confidence: 99%

Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review

McAlinden

2013

Eye

View full text Add to dashboard Cite

Purpose Systemic review to compare selective laser trabeculoplasty (SLT) to other glaucoma treatment options in terms of their intraocular pressure (IOP)-lowering effect. Methods Searches of the following databases were performed: PubMed, Cochrane Central Register of Controlled Trials, Ovid, EMBASE, metaRegister of Controlled Trials, and ClinicalTrials.gov. Only randomised controlled trials (RCTs) published in peer-reviewed journals comparing SLT to other glaucoma treatment options were considered. The main outcome measure was the change in IOP from baseline. Results An initial search of PubMed identified 23 RCTs with 17 meeting the inclusion criteria. Nine RCTs compared 1801 SLT to 1801 argon laser trabeculoplasty (ALT) and one trial compared 3601 SLT to 3601 ALT, all reporting no difference in terms of IOP reduction from baseline. One RCT reported better outcomes with SLT at 1 year but this effect regressed at 2 years. Three trials compared 3601 SLT to medical therapy and found no difference between the two treatment options. One trial found greater IOP reduction with latanoprost vs 901 and 1801 SLT, and greater IOP reduction with 1801 and 3601 SLT versus 901 SLT, however no differences were found between 3601 SLT versus latanoprost or 3601 vs 1801 SLT. Two trials compared 1801 SLT to 3601 SLT finding no difference in IOP reduction. Two trials compared 1801 SLT to 901 SLT, one finding no significant difference and one finding greater IOP reduction with 1801 SLT over 901 SLT. One trial compared excimer laser trabeculotomy (ELT) to 1801 SLT, finding no differences in IOP reduction up to 3 months follow-up but greater IOP reduction with ELT at time intervals between 9 and 24 months. There were no RCTs identified that compared SLT to surgery. Conclusion In terms of the IOP lowering effect, there is no difference between SLT and ALT. Three trials indicate no difference between 3601 SLT and medical therapy, with one of the trials indicating greater IOP reduction with latanoprost over 901 and 1801 SLT. Three trials indicate no difference between 1801 SLT and 3601 SLT. It is inconclusive whether 901 is less efficacious than 1801 SLT. One trial reports greater IOP reduction with ELT over 1801 SLT in the long term.

show abstract

Argon Versus Selective Laser Trabeculoplasty in Younger Patients

Abstract: In younger patients, both ALT and SLT have a significant ocular hypotensive effect 2 years after treatment, with no differences in outcome identified between the laser modalities.

Cited by 30 publications

References 0 publications

Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma

Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma

Correlation of Intraocular Pressure Between Both Eyes After Bilateral Selective Laser Trabeculoplasty in Open-angle Glaucoma

Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review

Contact Info

Product

Resources

About